Income Statement (TTM)
DMK Pharmaceuticals Corporation Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 3 | -0 | 4 | 4 | 2 | 2 | 1 | 1 | 5 | 5 | 5 | 4 |
| Change (%) | -63.64 | -117.77 | -942.11 | -2.60 | -45.44 | -10.80 | -59.65 | 81.91 | 228.92 | 6.28 | -0.65 | -27.92 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 9 | 6 | 4 | 6 | 7 | 7 | 6 | 5 | 5 | 6 | 7 | 6 | 5 |
| Change (%) | -31.26 | -29.11 | 42.59 | 2.37 | 4.96 | -5.55 | -17.06 | -0.24 | 15.21 | 5.24 | -5.03 | -19.64 | |
| % of Revenue | 120.53 | 227.87 | -908.80 | 153.88 | 161.74 | 311.14 | 329.45 | 677.25 | 371.41 | 130.10 | 128.83 | 123.15 | 137.30 |
| Gross Operating Profit | -2 | -4 | -5 | -2 | -2 | -5 | -5 | -5 | -4 | -1 | -1 | -1 | -1 |
| Change (%) | 126.48 | 40.23 | -55.02 | 11.61 | 86.60 | -3.07 | 1.51 | -14.47 | -63.53 | 1.82 | -20.23 | 16.13 | |
| % of Revenue | -20.53 | -127.87 | 1,008.80 | -53.88 | -61.74 | -211.14 | -229.45 | -577.25 | -271.41 | -30.10 | -28.83 | -23.15 | -37.30 |
| SG&A | 15 | 20 | 18 | 22 | 24 | 16 | 16 | 15 | 13 | 13 | 15 | 13 | 13 |
| Change (%) | 37.73 | -12.63 | 26.64 | 6.68 | -31.93 | -0.84 | -4.55 | -14.96 | 1.96 | 10.56 | -10.74 | -0.83 | |
| % of Revenue | 190.99 | 723.54 | -3,556.72 | 534.90 | 585.89 | 730.92 | 812.56 | 1,922.24 | 898.60 | 278.54 | 289.78 | 260.35 | 358.21 |
| R&D | 9 | 8 | 8 | 8 | 10 | 11 | 13 | 14 | 12 | 10 | 7 | 5 | 3 |
| Change (%) | -6.79 | 2.65 | -8.84 | 39.51 | 7.30 | 17.51 | 8.49 | -18.40 | -11.40 | -28.04 | -39.41 | -34.46 | |
| % of Revenue | 112.94 | 289.56 | -1,672.21 | 181.02 | 259.29 | 509.91 | 671.75 | 1,806.30 | 810.25 | 218.25 | 147.77 | 90.12 | 81.94 |
| OpEx | 32 | 34 | 30 | 36 | 41 | 34 | 36 | 35 | 30 | 30 | 29 | 24 | 21 |
| Change (%) | 6.29 | -12.09 | 19.34 | 12.75 | -15.90 | 4.24 | -1.99 | -14.11 | -0.88 | -3.98 | -16.92 | -12.12 | |
| % of Revenue | 424.46 | 1,240.96 | -6,137.73 | 869.80 | 1,006.92 | 1,551.97 | 1,813.76 | 4,405.80 | 2,080.25 | 626.88 | 566.38 | 473.62 | 577.45 |
| Operating Income | -25 | -32 | -31 | -32 | -37 | -32 | -34 | -34 | -29 | -25 | -24 | -19 | -17 |
| Change (%) | 27.85 | -2.83 | 3.92 | 14.75 | -12.64 | 5.28 | 1.37 | -16.34 | -12.48 | -5.93 | -20.41 | -7.89 | |
| % of Revenue | -324.46 | -1,140.96 | 6,237.73 | -769.80 | -906.92 | -1,451.97 | -1,713.76 | -4,305.80 | -1,980.25 | -526.88 | -466.38 | -373.62 | -477.45 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -0 | |||
| Change (%) | -91.45 | 1.04 | -82.46 | -28.34 | -60.86 | -100.00 | 27.71 | ||||||
| % of Revenue | -0.75 | -0.18 | -0.90 | -0.94 | -0.30 | -0.24 | -0.23 | 0.00 | -2.12 | -3.75 | |||
| Net Income | -35 | -49 | -58 | -54 | -55 | -46 | -41 | -40 | -32 | -26 | -25 | -25 | -22 |
| Change (%) | 39.43 | 16.47 | -6.28 | 1.85 | -16.54 | -10.96 | -2.25 | -19.96 | -17.06 | -5.33 | 0.71 | -11.93 | |
| % of Revenue | -463.83 | -1,778.84 | 11,655.71 | -1,297.23 | -1,356.57 | -2,074.91 | -2,071.15 | -5,017.95 | -2,207.87 | -556.72 | -495.92 | -502.69 | -614.21 |
Source: Capital IQ
